MA53226A - Sel et formes cristallines d'omecamtiv mecarbil - Google Patents
Sel et formes cristallines d'omecamtiv mecarbilInfo
- Publication number
- MA53226A MA53226A MA053226A MA53226A MA53226A MA 53226 A MA53226 A MA 53226A MA 053226 A MA053226 A MA 053226A MA 53226 A MA53226 A MA 53226A MA 53226 A MA53226 A MA 53226A
- Authority
- MA
- Morocco
- Prior art keywords
- salt
- crystalline forms
- omecamtiv mecarbil
- mecarbil
- omecamtiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
- C07C309/08—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862765090P | 2018-08-17 | 2018-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53226A true MA53226A (fr) | 2021-11-24 |
Family
ID=67809688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053226A MA53226A (fr) | 2018-08-17 | 2019-08-16 | Sel et formes cristallines d'omecamtiv mecarbil |
Country Status (8)
Country | Link |
---|---|
US (3) | US11465969B2 (fr) |
EP (1) | EP3837009A1 (fr) |
JP (1) | JP2021534138A (fr) |
AU (1) | AU2019321573A1 (fr) |
CA (1) | CA3108800A1 (fr) |
MA (1) | MA53226A (fr) |
MX (2) | MX2021001792A (fr) |
WO (1) | WO2020037164A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015023417B1 (pt) | 2013-03-14 | 2023-10-17 | Amgen Inc. | Formulação farmacêutica oral compreendendo hidrato de dicloridrato de omecamtiv mecarbil |
CA3063102A1 (fr) | 2017-06-30 | 2019-01-03 | Amgen Inc. | Synthese d'omecamtiv mecarbil |
AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
CR20200116A (es) | 2017-09-13 | 2021-04-28 | Amgen Inc | Compuestos de bisamida que activan el sarcómero y sus usos |
CA3108800A1 (fr) * | 2018-08-17 | 2020-02-20 | Amgen Inc. | Sel et formes cristallines d'omecamtiv mecarbil |
EP4031541A1 (fr) * | 2019-09-19 | 2022-07-27 | Synthon B.V. | Sels d'omecamtiv mecarbil et formes solides de ceux-ci |
US20220348543A1 (en) * | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
WO2022177927A1 (fr) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil |
KR20240006498A (ko) | 2021-03-10 | 2024-01-15 | 암젠 인크 | 오메캄티브 메카빌의 합성 |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
MXPA06014495A (es) | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
BR112015023417B1 (pt) | 2013-03-14 | 2023-10-17 | Amgen Inc. | Formulação farmacêutica oral compreendendo hidrato de dicloridrato de omecamtiv mecarbil |
MX2015012416A (es) | 2013-03-14 | 2016-04-07 | Amgen Inc | Compuestos heterociclicos y sus usos. |
US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
EP3313444B1 (fr) | 2015-06-26 | 2020-10-21 | Amgen Inc. | Traitement combiné comprenant un activateur de la myosine cardiaque et un inhibiteur des canaux if du noeud sinusal |
AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
CA3063102A1 (fr) | 2017-06-30 | 2019-01-03 | Amgen Inc. | Synthese d'omecamtiv mecarbil |
SI3594199T1 (sl) | 2018-07-09 | 2020-10-30 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Kristalinični 2-fluoro-3-nitrotoluen in postopek za njegovo pripravo |
EP3820851A1 (fr) | 2018-07-12 | 2021-05-19 | Assia Chemical Industries Ltd | Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl |
CA3108800A1 (fr) * | 2018-08-17 | 2020-02-20 | Amgen Inc. | Sel et formes cristallines d'omecamtiv mecarbil |
US20220042055A1 (en) | 2018-12-18 | 2022-02-10 | Amgen Inc. | Method of reducing aromatic nitro compounds |
US20220348543A1 (en) | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
EP4031541A1 (fr) | 2019-09-19 | 2022-07-27 | Synthon B.V. | Sels d'omecamtiv mecarbil et formes solides de ceux-ci |
US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
EP4041198A4 (fr) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés |
CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
AU2021221106A1 (en) | 2020-02-10 | 2022-09-22 | Amgen Inc. | Omecamtiv mecarbil tablet |
US20220184068A1 (en) | 2020-11-12 | 2022-06-16 | Cytokinetics, Inc. | Methods of treating heart failure by administering omecamtiv mecarbil |
KR20240006498A (ko) | 2021-03-10 | 2024-01-15 | 암젠 인크 | 오메캄티브 메카빌의 합성 |
-
2019
- 2019-08-16 CA CA3108800A patent/CA3108800A1/fr active Pending
- 2019-08-16 MX MX2021001792A patent/MX2021001792A/es unknown
- 2019-08-16 MA MA053226A patent/MA53226A/fr unknown
- 2019-08-16 WO PCT/US2019/046726 patent/WO2020037164A1/fr unknown
- 2019-08-16 AU AU2019321573A patent/AU2019321573A1/en active Pending
- 2019-08-16 US US17/263,224 patent/US11465969B2/en active Active
- 2019-08-16 EP EP19762026.3A patent/EP3837009A1/fr active Pending
- 2019-08-16 JP JP2021507456A patent/JP2021534138A/ja active Pending
-
2021
- 2021-02-12 MX MX2023013372A patent/MX2023013372A/es unknown
-
2022
- 2022-09-02 US US17/929,645 patent/US11926592B2/en active Active
-
2024
- 2024-01-18 US US18/416,741 patent/US20240199550A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021534138A (ja) | 2021-12-09 |
US20240199550A1 (en) | 2024-06-20 |
WO2020037164A1 (fr) | 2020-02-20 |
US11926592B2 (en) | 2024-03-12 |
US20210221771A1 (en) | 2021-07-22 |
MX2023013372A (es) | 2023-11-27 |
US11465969B2 (en) | 2022-10-11 |
AU2019321573A1 (en) | 2021-03-04 |
US20230108971A1 (en) | 2023-04-06 |
MX2021001792A (es) | 2021-05-27 |
CA3108800A1 (fr) | 2020-02-20 |
EP3837009A1 (fr) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
DK3866587T3 (da) | Overvågning af husdyr | |
MA51066A (fr) | Inhibiteurs d'intégrine | |
MA51819A (fr) | Nouvelles formes cristallines | |
MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
MA41252A (fr) | Formes solides d'un inhibiteur d'ask 1 | |
MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
IL288062A (en) | Crystalline forms of tapamidis and its salts | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
IL279195A (en) | New salts and crystals | |
MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
DK3891267T3 (da) | Mikrobielle sammensætninger omfattende ellagitannin og fremgangsmåder for brug | |
MA46460A (fr) | Formes cristallines et salines de composés agonistes de ppar | |
MA53021A (fr) | Composition de diacide oligosaccharidique d'alginate | |
MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
FR3055905B1 (fr) | Methode de sexage precoce d'esturgeon | |
DK3725786T3 (da) | KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE | |
DK3749673T3 (da) | Krystallinsk form af bictegravir-natrium | |
IL284218A (en) | Crystalline and salt forms of organic compound and their pharmaceutical preparation | |
MA43549A (fr) | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants | |
MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
SG11202009262VA (en) | Salts of compounds and crystals thereof | |
IL277578A (en) | New salt forms of URAT-1 inhibitors | |
MA45691A (fr) | Formes solides d'inhibiteur de ttk |